<DOC>
	<DOC>NCT02143271</DOC>
	<brief_summary>This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis.</brief_summary>
	<brief_title>Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<criteria>Written informed consent Stable chronic renal disease patients receiving peritoneal dialysis for at least 16 weeks prior to the screening intact parathyroid hormone value ≥ 240 pg/mL at the screening Corrected serum calcium ≥ 8.4 mg/dL at the screening Patients with primary hyperparathyroidism Patients who received cinacalcet within 2 weeks prior to the screening Patients who began to take or changed the dose/dosing regimen of active vitamin D/its analogs, phosphate binders and/or calcium containing compounds within 2 weeks prior to the screening Patients who underwent parathyroidectomy and/or parathyroid intervention Patients with uncontrolled hypertension and/or diabetes Patients with severe heart disorder Patients with severe hepatic disease Patients who take investigational drug in another clinical trial within 12 weeks prior to the screening Patients who have been judged ineligible to participate in the study by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis</keyword>
</DOC>